GlassScriptPhysician profile
Steven R Budoff
NPI 1376517052
$30,634.96
in general payments reported to CMS, 2019-2025
40 companies · $5,801 in 2025
The $5,801 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,054 · 2020: $2,032 · 2021: $4,721 · 2022: $4,609 · 2023: $5,431 · 2024: $5,988 · 2025: $5,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,081.02 |
| Education | $138.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,555.38 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $3,249.75 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $2,884.03 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $2,405.66 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,976.29 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,527.85 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $1,467.79 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Acadia Pharmaceuticals INC | $1,457.04 | 2019-2024 | Nuplazid |
| Jazz Pharmaceuticals INC. | $1,442.66 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,352.53 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $1,157.76 | 2019-2025 | Fanapt |
| Axsome Therapeutics, INC. | $1,148.75 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $1,066.38 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $1,010.13 | 2020-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $888.42 | 2021-2025 | Qelbree, Qelbree |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $833.30 | 2024-2025 | Cobenfy |
| Corium, LLC | $651.16 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $434.66 | 2020-2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $335.94 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Allergan, INC. | $329.47 | 2019-2020 | |
| Tris Pharma INC | $232.33 | 2023-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $174.72 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $162.04 | 2019-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $161.31 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $111.96 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $102.17 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $86.27 | 2019-2023 | Adzenys Xr-Odt |
| Owp Pharmaceuticals, INC. | $74.88 | 2023-2025 | Subvenite, Lamotrigine |
| Eisai INC. | $72.48 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $56.74 | 2024 | Horizant |
| Arbor Pharmaceuticals, INC. | $43.78 | 2019-2020 | |
| Shire North American Group INC | $37.58 | 2019 | |
| Adlon Therapeutics L.P. | $35.59 | 2019-2021 | |
| Noven Therapeutics, LLC | $27.93 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.11 | 2024 | |
| Janssen Biotech, INC. | $15.33 | 2023 | |
| Brainsway USA INC | $13.26 | 2019 | |
| Alfasigma USA, INC. | $12.66 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.46 | 2019 | |
| Neuronetics, INC. | $8.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Budoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.